Evidence map›Paper›PMID 37691070›Full record

ArticleRheumatology international2024

Ongoing shielding behavior one year post COVID-19: results from a longitudinal study of patients with inflammatory arthritis.

Melissa Sweeney, Lewis Carpenter, Savia de Souza, Hema Chaplin, Hsiu Tung, Emma Caton, James Galloway, Andrew Cope, Mark Yates, Elena Nikiphorou and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Melissa SweeneyHealth Psychology Section, Health Psychology Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Guy's Hospital, 5thFloor, Bermondsey Wing, Great Maze Pond, London, UK. Melissa.sweeney@kcl.ac.uk.ORCID 0000-0003-2635-0618
Lewis CarpenterHealth Psychology Section, Health Psychology Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Guy's Hospital, 5thFloor, Bermondsey Wing, Great Maze Pond, London, UK.ORCID 0000-0001-6889-7502
Savia de SouzaCentre for Rheumatic Diseases, King's College London, London, UK.ORCID 0000-0003-4953-3257
Hema ChaplinHealth Psychology Section, Health Psychology Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Guy's Hospital, 5thFloor, Bermondsey Wing, Great Maze Pond, London, UK.ORCID 0000-0002-9402-9669
Hsiu TungHealth Psychology Section, Health Psychology Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Guy's Hospital, 5thFloor, Bermondsey Wing, Great Maze Pond, London, UK.ORCID 0000-0002-1400-4585
Emma CatonHealth Psychology Section, Health Psychology Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Guy's Hospital, 5thFloor, Bermondsey Wing, Great Maze Pond, London, UK.ORCID 0000-0002-7612-7089
James GallowayCentre for Rheumatic Diseases, King's College London, London, UK.ORCID 0000-0002-1230-2781
Andrew CopeCentre for Rheumatic Diseases, King's College London, London, UK.ORCID 0000-0001-6735-5496
Mark YatesCentre for Rheumatic Diseases, King's College London, London, UK.ORCID 0000-0001-5449-5211
Elena NikiphorouCentre for Rheumatic Diseases, King's College London, London, UK.ORCID 0000-0001-6847-3726
Sam NortonHealth Psychology Section, Health Psychology Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Guy's Hospital, 5thFloor, Bermondsey Wing, Great Maze Pond, London, UK.ORCID 0000-0003-1714-9963
Guy's Hospital · GBKing's College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many patients with inflammatory arthritis (IA) were instructed to shield during the COVID-19 pandemic. Despite the ending of lockdowns and vaccination, large proportions of IA patients were continuing to shield when it is no longer needed. Given the detrimental effects of shielding on mental and physical health, understanding the rates and reasons for shielding is needed to help clinicians advise patients accordingly. This study was a 12-month prospective study following participants with IA during the COVID-19 pandemic. The proportions of IA patients shielding at each time point were calculated. Additionally, regressions and odds ratios for shielding were determined to assess medication type, mental health, and risk perception. While the extent of shielding fluctuated over the year of lockdowns, nearly all IA patients (93.5%) were still engaging in some shielding in 2021, with nearly half (43%) still shielding most or all of the time. Medications that were previously considered higher risk were not significantly associated with higher rates of shielding (OR = 1.60, p = 0.29), but greater symptoms of depression in June 2020 (OR = 1.07, p = 0.03) was both associated with increased the odds of shielding in June 2021. The high rates of IA patients continuing to shield in 2021 put more strain on patients and professionals as social isolation is linked with worsening mental and physical health, as well as greater difficulty with self-management. It is important for clinicians to be aware of this trend to ease the stress on patients.

Indexed as

ArthritisCOVID-19Communicable Disease ControlHumansLongitudinal StudiesPandemicsProspective StudiesCOVID-19Inflammatory arthritisMental healthShielding

Identifiers

PMID37691070
PMCPMC10766775
OpenAlexW4386593395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.